In This Issue
Summer Bridge on Advanced Biomanufacturing for Medicines
June 16, 2025 Volume 55 Issue 2
This issue of The Bridge features cutting-edge perspectives on the rapid progress and innovation in advanced biomanufacturing for medicines.
Articles In This Issue
  • Monday, June 16, 2025
    AuthorJohn L. Anderson
    Election to the National Academy of Engineering (NAE) is a great honor for any engineer. Yet, the purpose of our organization is not primarily honorific. The NAE exists to serve: to advance the welfare and prosperity of the nation by providing independent advice on matters involving engineering and ...
  • Monday, June 16, 2025
    AuthorBarry C. Buckland and Kelvin H. Lee
    In the fall of 2013, Professors Phillip A. Sharp and ­Robert Langer guest edited an issue of The Bridge on the theme of the Convergence of Engineering and the Life Sciences. The collection forecast the breadth in manufacturing approaches, capabilities, and innovation that would define the ...
  • Monday, June 16, 2025
    AuthorJ. Christopher Love
    Maintaining US leadership in the biomanufacturing sector requires investment in groundbreaking biomanufacturing technologies.
    Biopharmaceuticals have become essential medicines for preventing and treating diseases ranging from cancer and autoimmune disorders to ­neurological conditions, ...
  • Monday, June 16, 2025
    AuthorPaul C. Collins
    The new era of creativity and diversity of treatment modality in the biopharmaceutical industry has accelerated the need to adopt new platforms.
    “Platform” is a term that is often used in the biopharmaceutical manufacturing industry, but with different connotations and intentions ...
  • Monday, June 16, 2025
    AuthorKatharina S. Yandrofski, Megan H. Cleveland, Zvi Kelman, Mike J. Tarlov, and John P. Marino
    The NIST Biomanufacturing Program has made significant progress in antibody manufacturing and provides an approach to analytical measurements that can expedite the time to market of life-saving products and enable broader access to them.
    Monoclonal antibody (mAb) therapeutics, currently the ...
  • Friday, June 13, 2025
    AuthorChris Williams, Eric Hacherl, Tim Charlebois, Erik Barton, Stephen Kaminsky, Brenna Kelley-Clarke, Angie Snell Bennett, Marco Th
    A promising model for gene therapy development is outlined that supports a thriving gene therapy community and increases access to therapies, particularly for patients with rare and ultra-rare diseases.
    Developing gene therapies for rare diseases faces significant challenges, including high ...
  • Friday, June 13, 2025
    AuthorMelanie Tomczak and Penny Norquist
    Leveraging cutting-edge bioindustrial manufacturing technologies will enhance domestic supply chain resilience.
    From natural disasters and cyberattacks to growing sociopolitical tensions around the world, global supply chains are more unstable than any time in recent history. This instability ...
  • Friday, June 13, 2025
    AuthorMruthula Rammohan, Akash Vaidya, Spencer ­Grissom, Rachel Silvestri, Christopher Pirner, Kevin Solomon, and Mark Blenner
    There is great potential for synthetic biology to improve biopharmaceutical manufacturing, but fully unleashing it requires technical innovation and solutions that address ethical, legal, security, and societal implications.
    Synthetic biology has already shown its usefulness in biopharmaceutical ...
  • Thursday, June 12, 2025
    AuthorJerry Branson and Randy Roush
    A lifelong approach to engineering education can help restore the United States’ position as a global leader of technology.
    In the rapidly evolving landscape of engineering and technology, rethinking how science, technology, engineering, and mathematics (STEM) are taught over an ...